Determinants of discontinuation of ropinirole or pramipexole treatment in patients with Parkinson's disease: a retrospective study.

Determinants of discontinuation of ropinirole or pramipexole treatment in patients with Parkinson's disease: a retrospective study. - Ropinirole and pramipexole discontinuation.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31064

Enrollment

100

Registered

2009-02-11

Start date

2007-08-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Outpatients with Parkinson's disease, who gave informed consent to obtain their drug history, and who had at least one prescription ropinirole and/or pramipexole, and who give informed consent for this study.

Exclusion criteria

Exclusion criteria: No exclusion criteria will be applied.

Design outcomes

Primary

Measure	Time frame
The endpoint of our retrospective cohort is the combined discontinuation of ropinirole or pramipexole treatment. The main study parameter is a Dopamine receptor (DR)D3 polymorphism.	—

Secondary

Measure	Time frame
Other study parameters such as gender, age at the index date, daily levodopa dosage, the average dose of dopamine agonist, concomitant use of antiparkinsonian drugs, antidepressants or antipsychotics, duration of PD and a Chronic Disease Score. Also one other polymorphism of DRD3, and polymorphisms of DRD2 and DRD4.	—

Countries

Netherlands

Outcome results